NEUROTUNE
Mental health disorders, particularly depression and dementia, significantly challenge healthcare systems worldwide. The World Health Organization reports that 3.8% of the global population suffers from depression, and over 55 million people live with dementia, with nearly 10 million new cases each year. Despite the high prevalence, effective treatment options are limited, and many patients are hesitant to use antidepressants due to potential side effects and lack of long-term benefits. Additionally, the adoption of new neuroscience-based treatments in clinical settings faces challenges such as gaps in collaboration between neuroscientists and clinicians, high research costs, and complex integration into clinical practices. To address these challenges, our project advances transcranial Direct Current Stimulation (tDCS) as a non-invasive treatment for neurological and mental health disorders. Our solution includes: Interdisciplinary Collaboration: Bringing together neuroscientists, medical experts, and healthcare leaders to close the gap between research and clinical practice, accelerating the implementation of tDCS innovations. Personalized tDCS Therapy: Utilizing MRI-based software to tailor tDCS therapy to individual patients, optimizing treatment effectiveness by customizing electrode placement and current intensity. Innovative tDCS Devices: Developing the Tes4me by I-cap tDCS, a portable device designed for both clinical and home use, featuring personalized caps for optimal treatment outcomes. Clinical Research and Protocol Development: Conducting clinical trials to validate the effectiveness of tDCS for conditions like dementia, Parkinson's disease, depression, and more, demonstrating significant improvements in patient outcomes. Strategic Partnerships and Market Expansion: Partnering with leading research centers and technology manufacturers to leverage expertise, support regional market expansion, and enhance clinical services. Through these solutions, we aim to improve treatment for mental health and neurological disorders, enhance patient outcomes, and advance the field of non-invasive brain stimulation.
Biotechnology And National Health
Neuro technologies
Total Estimated Duration of Implementation: 9 to 18 months The total duration may vary depending on the specific conditions of each region, such as regulatory timelines, infrastructure readiness, and the speed of adoption by local healthcare providers. By carefully planning and coordinating each phase of the implementation, we aim to ensure a smooth and effective introduction of our tDCS solutions to new markets
Following the successful launch of our tDCS (transcranial Direct Current Stimulation) solutions in Russia, where we hope to establish strong partnerships with leading research institutions and healthcare providers, we are now expanding into BRICS regions. These regions are chosen based on their market potential, healthcare infrastructure, regulatory environment, and the growing need for innovative treatments for neurological and mental health disorders.
Personalized Treatment: Our tDCS technology uses MRI data to tailor therapy to each patient, optimizing electrode placement and current intensity for better outcomes. Comprehensive Solutions: We offer a complete package for tDCS therapy, including personalized software, versatile hardware for clinical and home use, and custom research and development services. User-Friendly and Accessible: Our devices, like the Tes4me by I-cap tDCS, are portable, intuitive, and easy to use, making advanced neurostimulation therapy accessible to a broad audience. Proven Efficacy: Supported by extensive research, our technology has shown significant improvements in treating conditions like Parkinson's disease, depression, and chronic pain. Expert Team: Our interdisciplinary team of neuroscientists, clinicians, and healthcare leaders ensures our solutions are both scientifically robust and clinically relevant. Strategic Partnerships: Collaborations with top institutions like Sechenov University and the Moscow Institute of Physics and Technology keep our technology at the cutting edge. Scalable Expansion: Our focus on strategic investments and regional growth enables rapid market expansion and offers clinics unique opportunities to enhance their services.
- Successful completion of the Sechenov Tech accelerator program. - Presentations at the international conference in Lisbon 2024 and the Congress of Young Scientists in Sirius 2023. - Ranked among the top 100 projects in the "Strong Ideas for a New Time" initiative. - Project was presentated at the Morocco Medica Expo. https://www.sechenov.ru/pressroom/news/elektrostimulyatsiya-v-lechenii-psikhiatricheskikh-i-nevrologicheskikh-zabolevaniy/?ysclid=m02ey63ymo933392293 https://materlife.ru/sechenovskij-universitet-molodye-uchenye-pervogo-mgmu-predstavili-svoi-proekty-na-rossijskom-venchurnom-forume-2024/?ysclid=m02ez0d7vn934256115
https://www.researchgate.net/publication/380661534_Grapheme-color_synesthesia_induction_with_V4_transcranial_direct_current_stimulation https://doi.org/10.21518/ms2024-121
